US-based biopharma company Syndexa Pharmaceuticals secured $8.5m in series B1 funding from backers including MP Healthcare Venture Management (MPH), a venture capital firm which acts as a subsidiary of pharmaceutical concern Mitsubishi Tanabe Pharma Corporation and its parent company, Mitsubishi Chemical Holdings. Also participating in the B1 round was the founder of electronics hardware maker…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
